Biotech Values

[DewDiligence]

VRTX : Here’s the “prettified” table from the C208 study (copied from
#msg-43114192) to use as a reference while listening to the webcast
from AASLD that starts in about two hours.

 
 Study Arm                           RVR          SVR         
 TID Telaprevir + Pegasys   (n=40)   83% (n=33)   83% (n=33)    
 TID Telaprevir + Pegintron (n=39)   67% (n=26)   82% (n=32)    
 BID Telaprevir + Pegasys   (n=40)   80% (n=32)   85% (n=34)    
 BID Telaprevir + Pegintron (n=42)   69% (n=29)   81% (n=34)